Date: 2017-12-26
Type of
information: Clinical trial authorisation
phase: 1
Announcement: clinical trial authorization
Company: Peregrine Pharmaceuticals (USA - CA)
Product: AG-270
Action
mechanism:
Disease: tumor types carrying an MTAP deletion
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On December 26, 2017, Agios Pharmaceuticals announced that the FDA has completed their 30-day safety review of the investigational new drug (IND) application for AG-270, the development candidate targeting MTAP-deleted tumors, and has granted IND clearance to proceed with the proposed Phase 1 dose-escalation trial in multiple tumor types carrying an MTAP deletion. Agios expects to initiate the Phase 1 trial in the first quarter of 2018.
Is
general: Yes
